| Current Price | $39.76 | Mkt Cap | $1.3B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $39.76 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 342,722 |
| 52-Wk Range | $37.50 - $125.00 | Avg. Daily Vol. | 714,668 |
| Current Price | $39.76 | Mkt Cap | $1.3B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $39.76 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 342,722 |
| 52-Wk Range | $37.50 - $125.00 | Avg. Daily Vol. | 714,668 |
The best Bull and Bear pitches based on recency and number of recommendations.
https://www.fool.com/investing/2017/10/30/3-reasons-ive-been-aggressively-buying-intercept-p.aspx
I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good… More
Read the most recent pitches from players about ICPT.
Recs
TMFjimhalley
(55.08)
Submitted: 9/2/2020 10:47:32 AM :
Start Price:
$45.53
NASDAQ:ICPT Score:
+4.43
Company is too reliant on one drug and whether its lead drug gets approval as a treatment for NASH. However, that all changes if it does get approval.
Recs
egger88
(< 20)
Submitted: 4/19/2020 2:31:01 PM :
Start Price:
$74.67
NASDAQ:ICPT Score:
-53.51
this goes up and down in alot of volume
Recs
Bigsef77
(69.75)
Submitted: 2/19/2019 10:07:10 AM :
Start Price:
$62.44
NASDAQ:ICPT Score:
-56.05
Intercept up 23% premarket on positive OCA data
Feb. 19, 2019 7:43 AM ET|About: Intercept Pharmaceuticals (ICPT)|By: Douglas W. House, SA News Editor
Intercept Pharmaceuticals (NASDAQ:ICPT) is up 23% premarket on light volume following its announcement of positive results from a Phase 3 clinical trial, REGENERATE, evaluating obeticholic acid (OCA) in patients with liver fibrosis (scarring) due to nonalcoholic steatohepatitis (NASH).
The study met one co-primary endpoint, a statistically significant proportion of patients achieving at least one stage improvement in fibrosis with no worsening of NASH at month 18 (p=0.0002), but failed to meet the other, the proportion of patients achieving NASH resolution with no worsening of liver fibrosis. The FDA agreed that only one endpoint needed to be met in order to be judged successful.
The data will be presented at the European Association for the Study of the Liver (EASL): International Liver Congress in Vienna April 10 - 14.
The company plans to file a U.S. marketing application in H2.
See all stocks on the move »
Find the members with the highest scoring picks in ICPT.
alkusari (< 20) Score: +443.87
The Score Leader is the player with the highest score across all their picks in ICPT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| jjc007007 | 66.11 | 2/5/2014 |
|
5Y | $296.00 | -86.65% | +84.34% | +170.99 | 0 Comment | |
| Halffrenzy | 24.83 | 1/10/2014 |
|
5Y | $438.98 | -91.00% | +76.63% | +167.63 | 0 Comment | |
| vzwatmrk | < 20 | 1/10/2014 |
|
5Y | $455.50 | -91.32% | +76.27% | +167.60 | 0 Comment | |
| sinvestor | 71.29 | 1/14/2014 |
|
3M | $361.00 | -89.05% | +77.47% | +166.53 | 1 Comment | |
| kevrose31 | 78.95 | 1/10/2014 |
|
1Y | $373.00 | -89.40% | +75.86% | +165.27 | 0 Comment | |
| NewbiesRock | < 20 | 2/18/2014 |
|
5Y | $353.89 | -88.83% | +75.63% | +164.47 | 4 Comments | |
| kayakmastr | 83.65 | 1/13/2014 |
|
1Y | $339.87 | -88.37% | +76.09% | +164.46 | 0 Comment | |
| alexeysm | 58.27 | 1/13/2014 |
|
1Y | $339.87 | -88.37% | +76.09% | +164.46 | 0 Comment | |
| Figgie27 | < 20 | 1/13/2014 |
|
3M | $339.87 | -88.37% | +76.09% | +164.46 | 0 Comment | |
| Brandonrules | < 20 | 4/11/2014 |
|
5Y | $260.33 | -84.82% | +77.58% | +162.40 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
